Myasthenia gravis (MG) is a rare, acquired autoimmune syndrome in which pathogenic auto-antibodies attack key proteins at the neuromuscular junction—most often, the muscle nicotinic acetylcholine receptor—disrupting synaptic transmission. Often, the result is severe muscle weakness, fatigability, and disability in patients, which may be life threatening. In the last 30 – 40 years, significant advances in diagnosis and treatment of MG have reduced the burden of high mortality and severe disability, and more recently research has produced novel potential therapeutic targets, clearer definitions of MG clinical subtypes, and new clinical trials to improve treatment options. Yet, diagnosis remains problematic because of nonspecific and fluctuating symptoms, and available therapeutics primarily treat symptoms or involve global suppression of the immune system.
The Myasthenia Gravis Foundation of America and the New York Academy of Sciences present this 12th international conference to galvanize efforts among researchers studying autoimmune and neuromuscular junction disease and to encourage continued progress in the diagnosis and treatment of MG that will help to improve patient outcomes and quality of life. This 3-day international conference will feature topics that span basic, translational, and clinical neuroscience and immunology related to MG and other autoimmune and neuromuscular junction disorders.
Emma Ciafaloni, MD
University of Rochester
Matthew N. Meriggioli, MD, FAAN
University of Illinois College of Medicine
Robert L. Ruff, MD, PhD
Louis Stokes Cleveland Department of Veterans Affairs Medical Center and Case Western Reserve University
Gil I. Wolfe, MD
University at Buffalo School of Medicine and Biomedical Sciences
Young Investigator Travel Fellowships
On behalf of the Myasthenia Gravis Foundation of America, we are pleased to announce the following travel fellowship winners. Winners were chosen based on their application materials and outstanding abstract submissions. Each winner will receive waived conference registration and $1000 towards their travel and accommodation expenses to attend the conference.
Revital Aricha, PhD, The Weizmann Institute of Science
Eyal Ben-Ami, MSc, Technion-Israel Institute of Technology
Alejandro M. Gomez, MSc Maastricht University
Maartje G. Huijbers, MSc, Leiden University Medical Centre
Paraskevi Zisimopoulou, PhD, Hellenic Pasteur Institute
|Student / Postdoc / Fellow Member
|Nonmember Not for Profit
|Student / Postdoc / Fellow Nonmember
Myasthenia Gravis and other neuromuscular junction disease patients are eligible to register at NYAS member rates. For more information, please contact Ms. Melanie Koundourou at firstname.lastname@example.org or 212.298.8681.
This project is supported by Grant Number R13NS077665 from the National Institute of Neurological Disorders and Stroke (NINDS), the National Center for Advancing Translational Sciences (NCATS), and the Office of Rare Diseases (ORD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS, NCATS, ORD, or the National Institutes of Health.
For a full list of sponsors, please view the Sponsors tab.